News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Vical Incorporated (VICL) Updates Herpes Simplex Vaccine Development at ASGCT Conference


5/16/2012 9:53:32 AM

PHILADELPHIA, May 16, 2012 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that results from multiple animal studies with the company's Vaxfectin®-formulated plasmid DNA (pDNA) vaccines against herpes simplex virus type 2 (HSV-2) demonstrate proof of concept supporting the company's decision in early 2012 to advance toward clinical testing, which is expected to begin in 2013. Results from completed prophylactic and therapeutic studies in mice and therapeutic studies in guinea pigs included:

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES